title: Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials.
abstract: OBJECTIVE
  To assess the effect of cardioselective β-blockers on pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
  
  
  METHODS
  The Embase and MEDLINE™ databases and the Cochrane Controlled Trials Register were searched comprehensively to identify all relevant clinical trials in humans published between January 1966 and May 2011. Randomized, blinded, placebo-controlled trials that studied the effects of cardioselective β-blockers on the forced expiratory volume in 1 s (FEV(1)) and the responsiveness of the FEV(1) to β-agonist administration in patients with COPD were included in the analysis.
  
  
  RESULTS
  Five studies were identified: four of these assessed both cardioselective and nonselective β-blockers; one assessed only cardioselective β-blockers. The FEV(1) was shown to decrease by 0.14 l with nonselective β-blockers and by 0.03 l with cardioselective β-blockers. The responsiveness of the FEV(1) to β-agonist administration decreased significantly by 13.42% after nonselective β-blockers, but did not change significantly after cardioselective β-blocker administration.
  
  
  CONCLUSIONS
  This metaanalysis suggests that the use of β-blockers, especially cardioselective β-blockers, should not be contraindicated in patients with COPD.
authors: Department of Pulmonary Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
authors: Y
authors: Y
authors: Ni
authors: G
authors: G
authors: Shi
authors: H
authors: H
authors: Wan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D005541:Forced Expiratory Volume / Q000187:drug effects*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive; D016032:Randomized Controlled Trials as Topic
chemical_list: D000319:Adrenergic beta-Antagonists